Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8448846 | 1.00 | ESR1 (0.34) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL86734 | 0.85 | — | — | |
| SCHEMBL13900450 | 0.84 | EPHX2 (0.31) | — | |
| SCHEMBL13958737 | 0.84 | PLG (0.31) | — | |
| SCHEMBL18532317 | 0.80 | MEN1 (0.33) | — | |
| SCHEMBL11682560 | 0.79 | ESR1 (0.34) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL30097909 | 0.78 | ESR1 (0.37) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL6853815 | 0.78 | KMT2A (0.31) | — | |
| SCHEMBL2267415 | 0.76 | ESR2 (0.46) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL130642 | 0.76 | ESR2 (0.46) | ESR1ESR2CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| CN-119948027-A | SOS1 protein degradation agent and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4458830-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| US-20240240370-A1 | SYSTEMS AND METHODS FOR CONTINUOUS FABRICATION OF WOVEN COMPOSITE MATERIALS | WEAV3D, Inc. | 2024-07-18 | — | — | US | disclosed |
| CN-110981705-B | Method for preparing cyclohexane dimethylamine | 万华化学集团股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-107986943-B | Synthesis method of cyclohexanedimethanol, catalyst and application thereof | 万华化学集团股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-110981705-A | Method for preparing cyclohexane dimethylamine | 万华化学集团股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-9663500-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140363864-A1 | MICROORGANISMS AND METHODS FOR THE PRODUCTION OF 1,4-CYCLOHEXANEDIMETHANOL | GENOMATICA, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| EP-1204623-A2 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6284932-B1 | Method for producing alcohols containing cycloaliphatic groups | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-04 | — | — | US | disclosed |
| US-6252121-B1 | SEPARATION OF CYCLIC REACTANTS, CORRESPONDING PRODUCTS, NONPOLAR SOLVENT, ORGANOPHOSPHORUS LIGANDS AND CATALYST COMPLEX MATERIALS FROM MULTIPHASE REACTION PRODUCT FLUID HAVING POLAR AND NONPOLAR PHASES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION | 2001-06-26 | — | — | US | disclosed |
| WO-2001007382-A2 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
| JP-2000119213-A | PRODUCTION OF HYDROXYALDEHYDE | KAO CORP | 2000-04-25 | — | — | JP | disclosed |
| EP-0983220-A1 | METHOD FOR PRODUCING ALCOHOLS CONTAINING CYCLOALIPHATIC GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-08 | — | — | EP | disclosed |
| US-5911912-A | POLYMERS FOR LIQUID CRYSTAL POLYMERS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1999-06-15 | — | — | US | disclosed |
| WO-1998052892-A1 | METHOD FOR PRODUCING ALCOHOLS CONTAINING CYCLOALIPHATIC GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-26 | — | — | WO | disclosed |
| US-4053415-A | UNSATURATED POLYESTER ETHER HAVING A PHOTOCROSSLINKABLE MOIETY | FUJI PHOTO FILM CO., LTD. (JA) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | ESR1 1484/4885ESR2 1264/4885CYP3A4 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.